Representatives of The Society of Asthma, Allergy and Clinical Immunology of HCM City (HSAACI) and AstraZeneca Vietnam Company at the collaboration memorandum signing ceremony. — Photo courtesy of AstraZeneca Vietnam

HCM CITY — The Society of Asthma, Allergy and Clinical Immunology of HCM City (HSAACI) and AstraZeneca Vietnam recently signed a comprehensive strategic co-operation memorandum aiming at enhancing the capabilities of medical and community healthcare workers in managing and treating respiratory diseases, with a particular focus on bronchial asthma and chronic obstructive pulmonary disease (COPD).

Under the collaboration, which lasts from 2024 to 2025, HSAACI and AstraZeneca Vietnam will be pivotal in updating and magnifying the impact of asthma and COPD treatments, resulting in pronounced contributions to community healthcare. 

The two hope that their collaboration will contribute to raising public awareness about asthma and allergic diseases, encouraging individuals to proactively seek medical advice, and facilitating early detection and treatment.

In detail, HASAACI and AstraZeneca Vietnam will have regular medical training initiatives with core objectives of updating disease knowledge and fortifying diagnostic and treatment methodologies for HSAACI members.

They will update knowledge and enhance diagnostic, treatment, and management skills for asthma and chronic obstructive pulmonary disease (COPD), particularly among members of the HSAACI.

Furthermore, the two will strengthen scientific activities and improve the quality of the asthma and COPD management network in existing facilities, while also expanding the network to include additional healthcare establishments.

They will also work together in the mission of protecting and caring for asthma and COPD patients, reducing the burden of illness and mortality rates, and aiming towards a healthier community.

"This comprehensive strategic partnership will serve as a significant milestone, symbolising our long-term commitment and strengthened collaboration towards advancements in the management and treatment of asthma and COPD, benefiting the people of Việt Nam,” said Nitin Kapoor, chairman and general director of AstraZeneca Vietnam.

The prevalence rate of asthma in Việt Nam is 4.1 per cent and COPD is 4.2 per cent, with COPD being the third leading cause of death. 

Statistics also show these two diseases are growing globally due to the rising number of smokers and environmental pollution. — VNS